Drs. Kenneth and Jonathan Nash Restore Chewing Power with Implant Supported Dentures in Jackson, MS

Functionally, a dental implant can be restored to act as a natural tooth. You can eat what you want to eat with it and you treat it as a natural tooth, flossing and brushing it every day.

Jackson, MS (PRWEB)
November 14, 2019

Denture-wearing patients in Jackson, MS can stabilize their prosthesis at Nash Family Dentistry through implant supported dentures. Dental implants give denture-wearers a more stable, comfortable and oftentimes permanent new smile as a solution to missing teeth. Implant supported dentures offer numerous benefits to patients over traditional dentures, bridges or flippers.

“The implant is simply a titanium screw that fits into the space that is left from missing teeth,” says Dr. Jonathan Nash. “Functionally, a dental implant can be restored to act as a natural tooth. You can eat what you want to eat with it and you treat it as a natural tooth, flossing and brushing it every day.”

Implant supported dentures are designed to look, feel and function as close to natural teeth as possible. With just two to four dental implants placed into the jawbone, a lifelike prosthesis can be attached and held firmly in place by the implants. Depending on your needs or what the dentists recommend, this new implant supported denture can be permanently attached or allowed to be removed at night or for cleaning. With either option, implant supported dentures provide patients with many benefits, including:

• No slipping, shifting or falling out
• Restoration of 55 to 90 percent bite strength
• Retained facial appearance
• Improved comfort
• Lasting many years

Dental implants work by placing a biocompatible titanium post to the jawbone where teeth are missing. With implant supported dentures, only two to four implants are needed, and they are placed in areas of the jaw with the most bone, often making bone grafting treatments unnecessary. Once fully healed, these implants can support a denture by “snapping” into it, making it stable in the mouth. Traditional dentures only provide patients with around ten percent bite strength, but when attached to dental implants, patients are restored with up to 90 percent of their natural biting and chewing power.

For many patients, implant supported dentures are a life changing solution to missing teeth. Being able to bite, chew, talk and act comfortably in front of others drastically improves self-esteem and lifestyle. Nash Family Dentistry also can replace individual missing teeth with implants and treat peri-implantitis, an infection of the gum tissue around implants, so patients are able to protect their dental implant investment. To make implant supported denture surgery more gentle and easier for patients, the dentists offer soothing sedation dentistry, including oral sedation and nitrous oxide.

Those interested in securing their dentures with implant supported dentures in Jackson, MS are encouraged to contact Nash Family Dentistry by calling 601-634-1812 or visiting http://www.vicksburgdentist.com.

About the Dentists

Nash Family Dentistry is a general practice offering personalized dental care for patients in Vicksburg, MS. Dr. Kenneth Nash, Dr. Jonathan Nash and their team provide patients with the latest in dental technology in a comfortable and welcoming environment. Drs. Nash offer a variety of services including laser dentistry, dental implants, and cosmetic dentistry services, among others. To learn more about the services offered at Nash Family Dentistry please visit the website at http://www.vicksburgdentist.com or call 601-634-1812 to schedule an appointment.

Share article on social media or email:

MaintenX team members ran in the 7th annual Treasure Chests 5K + Fun Run.

MaintenX believes that giving back to the community is an important part of business success.

TAMPA, Fla. (PRWEB)
November 14, 2019

MaintenX International, a Tampa-based facility maintenance provider, made strides toward providing more breast cancer research and patient services in Tampa Bay at the 7th Annual Treasure Chests 5K and Fun Run. More than 35 MaintenX team members ran in the charity race put on by the Tampa Bay Buccaneers and powered by Jabil.

“We are proud of our MaintenX team members who took time from their schedule to show their support for this worthy cause,” said Mary Ann Velez, MaintenX’s National Director of Service, who organized the company run for the second year. “We are glad we can show our support to employees or their family members who are familiar with this terrible disease.”

MaintenX covered the registration costs of any team member that wanted to participate in the event. MaintenX team members were among the top time finishers, including Jorge Bravo, Matthew Colon, Dan Fish and Luis Torres who finished in the top 300 men and Tracy Gaw and Emy Calix who finished within the top 400 female runners. With more than 2000 runners overall, MaintenX is proud to have been able to raise funds and have a competitive showing at the race.

All runners had the opportunity to cross the finish line in the Bucs state-of-the-art indoor practice facility and opportunity to stay and watch the Bucs take on the Arizona Cardinals in their breast cancer awareness game. Proceeds from the run benefitted community organizations focused on breast health, including the Advent Health Foundation, American Cancer Society, Florida Cancer, and Moffit Cancer Center.

MaintenX believes that giving back to the community is an important part of business success. In addition to the Treasure Chests 5K, MaintenX has given back to a number of community organizations including sponsoring homes with Habitat for Humanity, volunteering at Home Depot Foundation service events and providing hundreds of gifts for children in need through the Salvation Army’s Angel Tree program.

For additional information about the Treasure Chest 5K and Fun Run, visit https://www.buccaneers.com/race/

To learn more about MaintenX and their commitment to superior service and customer satisfaction, visit http://www.maintenx.com.

ABOUT MAINTENX INTERNATIONAL:

MaintenX International is a fully-licensed, facilities repair company. They are one of the largest national self-performing facility maintenance and repair companies in the U.S. MaintenX has created a network of knowledgeable and professional technicians throughout the country. With their team of well-trained technicians, MaintenX self-performs and manages facility maintenance for clients. In the event there is not a MaintenX technician in the area, the company has fostered a network of preferred vendor partners throughout the country to provide superior service for their clients. For more than 40 years, MaintenX has been expertly serving multi-location retail stores, restaurant chains, and Fortune 500 companies nationwide.

Share article on social media or email:

“We believe that FDA approval of this treatment will not only help our patients, but will also open the door to increased interest in NF, as a validation of the power of working together to find cures for patients who most need them,” said Annette Bakker, PhD, Children’s Tumor Foundation President.

NEW YORK (PRWEB)
November 14, 2019

AstraZeneca and MSD (Merck) announced today that the U.S. Food and Drug Administration (FDA) has granted acceptance to file status of its application for the MEK inhibitor selumetinib, for use in patients with plexiform neurofibromas, a common manifestation in the disease neurofibromatosis type one (NF1). The FDA’s acceptance of the application is a major milestone for selumetinib becoming the first ever approved treatment for NF patients. This follows previous designations from the FDA granting the treatment orphan drug status as well as breakthrough status, and now enters the drug into the FDA’s approval pipeline. The FDA also granted priority review, and a PDUFA (Prescription Drug User Fee Act) has been set for the second quarter of 2020.

This application follows comprehensive clinical testing of the drug in patients at the National Cancer Institute (NCI), a division of the National Institutes of Health (NIH). In those clinical trials, over 70% of NF patients with inoperable plexiform neurofibromas saw tumor size reduction anywhere from 20-55% in size. In addition to both visible and actual tumor reduction, patients reported higher-quality physical function, improved mobility, and enhanced emotional and psychological status.

The first use of MEK inhibitors as a potential treatment for NF tumors came from an early-stage discovery by Children’s Tumor Foundation (CTF)-funded researchers, who showed that the repurposed oncology drug selumetinib could affect NF tumor size. Positive early clinical results were first reported at CTF’s annual scientific NF Conference in 2015, as well as in a subsequent publication in the New England Journal of Medicine.

Collaborative efforts among the NCI, the NIH, the NFRP-CDMRP (Neurofibromatosis Research Program of the Congressionally Directed Medical Research Programs), NTAP (Neurofibromatosis Therapeutic Consortium), and CTF ensured that this ‘MEK Story’ proceeded efficiently and expeditiously through proactive and strategic coordination, which included patient input in the mix. A soon-to-be-published paper on this unique collaboration, and its potential application for other disease areas, will appear in EMBO Molecular Medicine. Other types of MEK inhibitors are also now in clinical trial, including mirdametinib from SpringWorks Therapeutics, a company which CTF helped spin off from Pfizer.

“Today’s announcement from AstraZeneca and MSD/Merck is a huge step towards our ultimate dream – approved treatments for neurofibromatosis,” said Annette Bakker, PhD, President of the Children’s Tumor Foundation. “We believe that FDA approval of this treatment will not only help our patients, but will also open the door to increased interest in NF, as a validation of the power of working together to find cures for patients who most need them.”

Founded in 1978, the Children’s Tumor Foundation is the world’s largest nongovernmental funder of all forms of neurofibromatosis research in the world. Its collaborative and open-data research model has catalyzed new discoveries and in recent years helped triple the number of clinical trials for NF, identified new drug candidates for both NF1 and NF2, and established a unique worldwide consortium focused on pain.

Neurofibromatosis is a genetic disorder that affects 1 in 3,000 births of all populations equally, and causes tumors to grow on nerves throughout the body. Its devastating effects can cause blindness, deafness, bone abnormalities, disfigurement, learning disabilities, disabling pain, and cancer.

To read the Astra Zeneca / MSD press release about today’s announcement, click here.

To read more about the MEK story collaboration, click here.

To view videos of the positive impact this treatment has on NF patients, watch Philip’s story here and Jane’s story here. Read the stories of other NF patients currently receiving this treatment here.

To learn more, visit the Children’s Tumor Foundation at ctf.org.

Share article on social media or email:

Adage Named Episerver Customer Success Partner of the Year

“We are extremely proud of our long-term customer relationships fostered with a hyper-focus on customer success throughout the Episerver community.” – Roy Chomko, President & CEO Adage Technologies

CHICAGO (PRWEB)
November 15, 2019

Adage Technologies, web strategy, design and development company in Chicago, IL has been recognized as the 2019 Episerver Customer Success Partner of the Year. The award recognizes Adage for its keen focus on customer success by consistently delivering on-time, on-budget and above-par experiences for its mutual customers with Episerver, the customer-centric digital experience company. Adage was honored at the annual Episerver Ascend conference, held last week in Miami.

An Episerver partner since 2009, Adage is the most experienced in North America with over 100 Episerver CMS and Commerce implementations. Adage collaborates with organizations to ensure shared goals are achieved and high standards of customer satisfaction are continually met.

Exceeding the expectations of all client-partners is what truly drives Adage. Roy Chomko, President & CEO of Adage explains, “This award means more to us than any other award we could have received. We are extremely proud of our long-term customer relationships fostered with a hyper-focus on customer success throughout the Episerver community. Everyone at Adage knows our commitment doesn’t stop with the completion of a project. We view our customers as partners with a joint mission to serve their customers online today and into the future.”

This year’s partner’s awards ceremony recognized partners in nine separate categories with common judging criteria including proof of customer success through partner expertise, platform implementation and project innovation with Episerver solutions. As Episerver Digital Customer Success Partner of the Year, Adage leveraged best-in-class design and development methodologies to deliver exceptional experiences for their customers’ customers, attaining continuity between what customers expect when they interact with brands online and what they actually get.

“As Episerver grows, so does its partner network and the competitiveness of the partner awards,” said Dom Citino, VP of worldwide partnerships at Episerver. “It’s getting more and more difficult for our teams to choose just one winner in each category which speaks to the diversity and depth of the Episerver partner network. Our focus is the customer and the experience they are able to provide their customers, and Adage shows us time and again that we share the same focus.”

Adage and Episerver share a common goal to ensure customers, and their customers meet their meaningful goals. Through a frictionless buyer journey, personalized experiences, accessibility considerations, and easy-to-find content, products or services, Adage and Episerver strive to improve the entire audience lifecycle from discovery to retention.

About Adage

Adage Technologies is a web strategy, design, development and ecommerce firm in downtown Chicago. We work with mission-based organizations to increase member and future member satisfaction through digital initiatives from web conversion optimization and member research to full-scale digital transformations. We implement solutions to tackle your organizations unique challenges. Learn more at adagetech.com.

About Episerver

Episerver empowers businesses to scale through the most customer-centric approach to digital experiences. Its Customer-Centric Digital Experience Platform™ features best-in-class content management, robust commerce, and intuitive data and personalization solutions. The platform has consistently earned industry, analyst and media recognition for its vision, capabilities and customer commitment. Episerver’s 900+ partners and 700+ employees in offices around the globe are proud to help more than 8,000 customers enrich their customer lifetime value, increase revenue and grow their brands. Learn more at episerver.com.

Share article on social media or email:

SVP Family

” …this is indeed a proud achievement. My congratulations go out to all…valuable staff members who serve our healthcare clients including OCLI and Island Eye Surgicenter on Long Island.” – Tom Burke, CEO Spectrum Vision Partners

GARDEN CITY, N.Y. (PRWEB)
November 15, 2019

Spectrum Vision Partners claimed 13th place in a list of over 100 employers in Newsday’s Top Long Island Workplaces for 2019. The recently announced rankings honor those organizations where employees feel engaged, appreciated, and empowered.

During the selection process, Newsday worked in partnership with Energage to conduct surveys into organizational health and identify Long Island workplaces where employees feel their work is valued; where they identify with the company’s goals and vision; and where they express confidence in their leadership. With employee surveys of over 100 companies, Spectrum Vision Partners was one of the groups’ recognized top performers.

“The Top Workplaces award is not a popularity contest,” said Doug Claffey, CEO of Energage. “Organizations must meet high standards in the eyes of their employees. People often mistakenly assume it’s all about pay, fancy perks, and benefits. It’s really about organizational health, and that starts with good leadership. Having a good workplace is essential for hiring, retaining, and motivating talent.”

Tom Burke, CEO of Spectrum Vision Partners, was pleased with the results. “It’s nice to see Spectrum honored as a winning company and to receive some well-deserved recognition for the good things we accomplish. As a fairly large employer competing with private businesses, nonprofits, and government organizations, this is indeed a proud achievement. My congratulations go out to all the doctors, managers, administrators, HR team, and other valuable staff members who serve our healthcare clients including OCLI and Island Eye Surgicenter on Long Island.”

SVP administratively supports the growth and management of some of the leading ophthalmology practices and eye ambulatory surgery centers in the New York, New Jersey, and Connecticut Tri-State area. Managed practices include OCLI, Island Eye Surgicenter, Ophthalmic Consultants of Connecticut (OCC), New Vision Cataract Center, Long Island Eye Care, Eye Institute of New York, Glaucoma Associates of Long Island, Precision Eye Care, and Huntington Eye Care.

In its first year of business, SVP grew from 400 employees to a current total of nearly 800. The organization recently relocated to a new corporate service center in order to provide improved customer service. SVP offers its network of multi-specialty ophthalmologists a complete range of business services.

About Spectrum Vision Partners

Spectrum Vision Partners (http://www.spectrumvisionpartners.com) is a leading management services organization, serving the ophthalmology sector. Spectrum Vision Partners has over 700 employees, providing world-class practice management solutions to a network of nationally renowned, multi-specialty ophthalmologists in the New York, New Jersey, Connecticut Tri-State region. The Spectrum platform in New York and Connecticut consists of 26 clinic locations, two State Licensed Ambulatory Centers, with 71 surgeons, doctors, and other medical professionals. Spectrum Vision Partners provides a comprehensive set of business support functions, including billing and collections, credential services, marketing, physician recruitment, ASC development, financial and accounting services, benefits and payroll management, and information technology. The company’s corporate service center is located at 825 East Gate Boulevard, Suite 111, Garden City, NY 11530.

About OCLI

Founded in 1997, OCLI (http://www.ocli.net) is one of the leading ophthalmology practices in the United States. OCLI boasts 21 state-of-the-art medical facilities across Manhattan, Nassau, and Suffolk counties, housing the most advanced technology available, to offer patients a variety of ophthalmic services and treatments. OCLI is led by 42 highly skilled eye surgeons in each major sub-specialty of eye care, providing comprehensive eye care services, including treatment for cataracts, corneal disease, refractive surgery, glaucoma, oculoplastics, retinal disease, and neuro-ophthalmology. OCLI also employs six Doctors of Optometry, three Physician Assistants, and one NYS Licensed Aesthetician.

About Island Eye Surgicenter

Island Eye is a New York State licensed and Medicare Certified Ambulatory Surgery Center and Tissue Transplantation facility. The center is also accredited by the Accreditation Association for Ambulatory Health Care (AAAHC), a national nonprofit organization ensuring that ambulatory facilities maintain the highest standards of safety and medical care.

Since the beginning, Island Eye Surgicenter’s mission has been to provide excellence in surgical eye care, and it remains a “Center of Excellence.” The physicians of Island Eye Surgicenter are some of the most prominent medical professionals in the nation. They contribute to the development of the latest ophthalmic advancements and lecture on a range of subjects pertaining to surgical eye care throughout the United States and the around world.

About Ophthalmic Consultants of Connecticut (OCC)

Ophthalmic Consultants of Connecticut (http://www.occeye.com) is one of the leading combined ophthalmology/optometry practices in Connecticut. OCC boasts 4 state-of-the-art medical facilities across Connecticut, housing the most advanced technology available to offer patients a variety of ophthalmic services and treatments. OCC is led by 3 highly skilled eye surgeons as well as 3 residency trained optometrists specializing in providing comprehensive eye care services, including treatment for cataracts, corneal disease, refractive surgery, and glaucoma.

About New Vision Cataract Center

New Vision Cataract Center (http://www.newvisioncataractcenter.com) is a leading ambulatory surgery center specializing in eye surgeries. NVCC has 2 operating rooms and a laser suite and has been serving the Connecticut region for over 20 years.

Pictured left to right: Frank A. Calamari, David J. Arena, Kelly C. Coffey, Michael J. Brescia, MD, Thomas J. Fahey, Jr., MD, and Carlos M. Hernandez.

NEW YORK (PRWEB)
November 15, 2019

At their 36th Annual Awards Gala on November 12th at The Pierre Hotel in New York City, Calvary Hospital raised more than $750,000 for programs and services benefiting Calvary patients and their families. Ryan Field, WABC-TV Sports Anchor, served as the master of ceremonies. This year’s event also featured entertainment from The Chiffons, and Shirley Alston Reeves, original lead singer of The Shirelles.

Carlos M. Hernandez, Head of Global Banking, JPMorgan Chase & Co., and chairman of

the Board of the Calvary Fund presented The Calvary Medal to Kelly C. Coffey, chief executive officer of City National Bank, and David J. Arena, head of global real estate for JPMorgan Chase & Co. Ms. Coffey and Mr. Arena were recognized for their distinguished corporate and civic leadership and outstanding philanthropic commitment to the Calvary mission.

The event also included a special presentation of The Calvary Medal and the Annie Blount Storrs Award to Michael J. Brescia, MD, in recognition of his visionary leadership for the Hospital. During his 56-year tenure, Dr. Brescia has spearheaded Calvary’s family-centric approach to patient care, helped the Hospital earn its global reputation as a leader in palliative care, and expanded care to patients and families from diverse religious and cultural backgrounds.

“Our objective with each Calvary Annual Gala is to honor individuals whose leadership and career achievements are aligned with the Hospital’s mission of providing excellence in care,” said Mr. Hernandez. “Ms. Coffey, Mr. Arena and Dr. Brescia, have all met these criteria over their respective careers. We are delighted to recognize them for their commitment to Calvary’s mission of caring for people at a most sacred time in their lives.”

Since 1899, Calvary has been the nation’s only fully accredited acute care specialty hospital devoted exclusively to providing palliative care to adult patients with advanced cancer and other life-limiting illnesses. Each year, thousands of patients receive CalvaryCareSM throughout the greater New York area. To learn how Calvary can help you and your family, please visit: http://www.calvaryhospital.org Follow us on Facebook, LinkedIn or Instagram (handle “calvarycare”).

Share article on social media or email: